Cite

    Trelinska, J. et al. (2015). Complications of mammalian target of rapamycin inhibitor anticancer treatment among patients with tuberous sclerosis complex are common and occasionally life-threatening. Anti-cancer drugs. 26 (4), p. . [Online].